{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:27:07Z","timestamp":1791390427203,"version":"4.3.3"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2026,8,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>There is evidence for a causal role of Epstein\u2013Barr virus (EBV), a known carcinogen, in an increasing number of lymphoma subtypes, but a systematic evaluation of EBV attributable fraction is lacking. We conducted a systematic review and meta\u2010analysis of EBV prevalence in lymphoma subtypes from 1990 to 2024, stratified by HIV status and geographical region. For each subtype, we calculated pooled prevalence and corresponding 95% confidence intervals (CIs) of EBV, measured by EBV\u2010encoded RNA in\u00a0situ hybridisation. 307 eligible studies, including &gt;\u200921,140 lymphoma cases, were included. In HIV\u2010negative persons, EBV pooled prevalence was 10.8% (95% CI 8.6%\u201313.5%) in Diffuse large B\u2010cell lymphoma (DLBCL), 45.8% (35.2%\u201356.8%) in Burkitt lymphoma (BL), 53.0% (46.9%\u201358.9%) in Hodgkin lymphoma, 52.5% (29.6%\u201374.4%) in plasmablastic lymphoma, 92.4% (83.3%\u201396.7%) in extranodal NK\/T\u2010cell lymphoma (ENKTL), and 5.1% (2.7%\u20139.4%) in follicular lymphoma. EBV prevalence was higher among tumors diagnosed among persons living with HIV (PLHIV), for DLBCL (43.6% (95% CI 31.5%\u201356.5%)), BL (43.3% (27.9%\u201360.2%)), and PBL (79.4% (65.6%\u201388.6%)), compared to HIV\u2010negative tumors. BL was the only subtype with evidence of heterogeneity in EBV positivity by region, with near\u2010universal EBV positivity in East African BL. This provides the first systematic and comprehensive evidence on EBV's substantial contribution to lymphoma, highlighting its particular importance in lymphomas arising in PLHIV. These data can contribute to estimating the complete burden of EBV\u2010related disease and inform public health and clinical strategies, including vaccines, early diagnosis, or targeted therapies.<\/jats:p>","DOI":"10.1002\/ijc.70468","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T04:38:56Z","timestamp":1775623136000},"page":"896-903","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Attributable Fraction of Epstein\u2013Barr Virus in Subtypes of Lymphoma: A Systematic Review and Global Meta\u2010Analysis"],"prefix":"10.1002","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-6499","authenticated-orcid":false,"given":"Mayo","family":"Hirabayashi","sequence":"first","affiliation":[{"name":"Division of Prevention, Institute for Cancer Control National Cancer Center  Tokyo Japan"},{"name":"International Agency for Research on Cancer (IARC\/WHO), Early Detection, Prevention and Infections Branch  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Georges","sequence":"additional","affiliation":[{"name":"International Agency for Research on Cancer (IARC\/WHO), Early Detection, Prevention and Infections Branch  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Damien","family":"Combes","sequence":"additional","affiliation":[{"name":"International Agency for Research on Cancer (IARC\/WHO), Early Detection, Prevention and Infections Branch  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7534-333X","authenticated-orcid":false,"given":"Gary M.","family":"Clifford","sequence":"additional","affiliation":[{"name":"International Agency for Research on Cancer (IARC\/WHO), Early Detection, Prevention and Infections Branch  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(64)91524-7"},{"issue":"50","key":"e_1_2_11_3_1","first-page":"18093","article-title":"Peripheral B Cells Latently Infected With Epstein\u2013Barr Virus Display Molecular Hallmarks of Classical Antigen\u2010Selected Memory B Cells","volume":"102","author":"Tatyana A. S.","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1452"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj8222"},{"key":"e_1_2_11_6_1","volume-title":"IARC Monographs on the Evaluation of Carcinog Enic Risks to Humans","author":"International Agency for Research on Cancer","year":"2012"},{"key":"e_1_2_11_7_1","volume-title":"Cancer IAfRo ed. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans","author":"IARC","year":"1997"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30488-7"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.07.042"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01181-y"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00713"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_2_11_13_1","first-page":"1","article-title":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological Agents","volume":"100","year":"2012","journal-title":"IARC Monographs on the Evaluation of Carcinogenic Risks to Humans"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289561"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2009.1.523.0010523"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31537"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(16)30143-7"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2014.06.001"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.769218"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/523813"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01082-1"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2023.105579"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13652"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad012"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04558-0"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06188-w"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70468","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T07:06:11Z","timestamp":1782111971000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8,15]]}},"alternative-id":["10.1002\/ijc.70468"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70468","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"2025-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}